autologous base edited cd34+ hspcs beam-101
Generic: Autologous Base Edited CD34+ HSPCs BEAM-101
autologous base edited cd34+ hspcs beam-101: 1 clinical trial tracked.
autologous base edited cd34+ hspcs beam-101 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about autologous base edited cd34+ hspcs beam-101, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)
Primary endpoint: Change in annualized number of severe VOCs (Vascular-occlusive Crisis) relative to baseline
Interventionalopen15 targetStarted 2022-08Completion 2028-0219 sites · United StatesBeam Therapeutics Inc.